RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1055/s-0041-1733825
Drug Repurposing in Oncology
Introduction
Several novel systemic cancer therapies have evolved in the last two decades. Oncology drug development has moved from “cytotoxic” agents to “targeted” drugs. More recently, immune modulation by drugs or cellular therapies has been added to anti-cancer armamentarium.[1] Advances in basic cancer biology have aided these developments. However, we are far from achieving “cure” or “control” of most advanced cancers. There is a constant need to innovate and develop therapies to “outwit” the ever-mutating cancer cell. Canonical drug development models are painstakingly slow and very expensive and hence there is need to look for alternative options. It is in this space that drug repurposing fits whereby an existing drug (used for other nononcological indications) is used for treating tumors by virtue of its action on some of the “targets” presented by cancer. The increased understanding of the hallmarks of cancer and the development of various data-driven approaches have facilitated the science of drug repurposing in oncology.[2]
Publikationsverlauf
Artikel online veröffentlicht:
07. August 2021
© 2021. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India
-
References
- 1 Falzone L, Salomone S, Libra M. Evolution of cancer pharmacological treatments at the turn of the third millennium. Front Pharmacol 2018; 9: 1300
- 2 Blackadar CB. Historical review of the causes of cancer. World J Clin Oncol 2016; 7 (01) 54-86
- 3 Pushpakom S, Iorio F, Eyers PA. et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 2019; 18 (01) 41-58
- 4 Zhang Z, Zhou L, Xie N. et al. Overcoming cancer therapeutic bottleneck by drug repurposing. Signal Transduct Target Ther 2020; 5 (01) 113
- 5 Sleire L, Førde HE, Netland IA, Leiss L, Skeie BS, Enger PØ. Drug repurposing in cancer. Pharmacol Res 2017; 124: 74-91
- 6 Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP, Vikas P. The repurposing drugs in oncology (ReDO) project. Ecancermedicalscience 2014; 8: 442
- 7 Juárez-López D, Schcolnik-Cabrera A. Drug repurposing: considerations to surpass while re-directing old compounds for new treatments. Arch Med Res 2020
- 8 Jourdan J-P, Bureau R, Rochais C, Dallemagne P. Drug repositioning: a brief overview. J Pharm Pharmacol 2020; 72 (09) 1145-1151
- 9 Soria-Castro R, Schcolnik-Cabrera A, Rodríguez-López G. et al. Exploring the drug repurposing versatility of valproic acid as a multifunctional regulator of innate and adaptive immune cells. J Immunol Res 2019; 2019: 9678098
- 10 Vargesson N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res C Embryo Today 2015; 105 (02) 140-156
- 11 Rehman W, Arfons LM, Lazarus HM. The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development. Ther Adv Hematol 2011; 2 (05) 291-308
- 12 Singhal S, Mehta J, Desikan R. et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341 (21) 1565-1571
- 13 Fonte C, Fatigoni S, Roila F. A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients. Crit Rev Oncol Hematol 2015; 95 (02) 214-221
- 14 Hesketh PJ, Kris MG, Basch E. et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2017; 35 (28) 3240-3261
- 15 Zarghi A, Arfaei S. Selective COX-2 inhibitors: a review of their structure-activity relationships. Iran J Pharm Res 2011; 10 (04) 655-683
- 16 Patil V, Noronha V, Dhumal SB. et al. Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial. Lancet Glob Health 2020; 8 (09) e1213-e1222
- 17 Palve V, Liao Y, Remsing Rix LL, Rix U. Turning liabilities into opportunities: off-target based drug repurposing in cancer. Semin Cancer Biol 2021; 68: 209-229
- 18 NewDrugs_CTRules_2019. New Drugs and Clinical Trials Rules 2019. [home page on Internet]. C2021 [updated 2019 Mar 19; cited 2021 Apr 06]. Available from: https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/NewDrugs_CTRules_2019.pdf. Accessed July 12, 2021
- 19 Hernandez JJ, Pryszlak M, Smith L. et al. Giving drugs a second chance: overcoming regulatory and financial hurdles in repurposing approved drugs as cancer therapeutics. Front Oncol 2017; 7: 273
- 20 Breckenridge A, Jacob R. Overcoming the legal and regulatory barriers to drug repurposing. Nat Rev Drug Discov 2019; 18 (01) 1-2
- 21 Zhang Z, Chen F, Shang L. Advances in antitumor effects of NSAIDs. Cancer Manag Res 2018; 10: 4631-4640
- 22 Joharatnam-Hogan N, Alexandre L, Yarmolinsky J. et al. Statins as potential chemoprevention or therapeutic agents in cancer: a model for evaluating repurposed drugs. Curr Oncol Rep 2021; 23 (03) 29
- 23 Yu H, Zhong X, Gao P. et al. The potential effect of metformin on cancer: an umbrella review. Front Endocrinol (Lausanne 2019; 10: 617
- 24 Guerini AE, Triggiani L, Maddalo M. et al. Mebendazole as a candidate for drug repurposing in oncology: an extensive review of current literature. Cancers (Basel 2019; 11 (09) E1284
- 25 Sheeley MP, Andolino C, Kiesel VA, Teegarden D, Vitamin D. Vitamin D regulation of energy metabolism in cancer. Br J Pharmacol 2021
- 26 Pounds R, Leonard S, Dawson C, Kehoe S. Repurposing itraconazole for the treatment of cancer. Oncol Lett 2017; 14 (03) 2587-2597
- 27 Wang L-H, Xu M, Fu L-Q, Chen X-Y, Yang F. The antihelminthic niclosamide inhibits cancer stemness, extracellular matrix remodeling, and metastasis through dysregulation of the nuclear β-catenin/c-Myc axis in OSCC. Sci Rep 2018; 8 (01) 12776
- 28 Xu R, Ji Z, Xu C, Zhu J. The clinical value of using chloroquine or hydroxychloroquine as autophagy inhibitors in the treatment of cancers: a systematic review and meta-analysis. Medicine (Baltimore 2018; 97 (46) e12912
- 29 Tang M, Hu X, Wang Y. et al. Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacol Res 2021; 163: 105207
- 30 Singhal S, Mehta J. Thalidomide in cancer: potential uses and limitations. BioDrugs 2001; 15 (03) 163-172